Moreover, applying the same criteria commonly used for PCa (for example, SUVmax values in dominant sites on 68Ga-PSMA PET/CT at least 1.5 times those of the SUVmean values in the liver) could be misleading, considering the different PSMA mechanisms of expression in non-prostatic tumors (namely in the endothelium of tumor microvessels) [26]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.